NeurAxis Inc (NRXS): Price-to-Revenue Coefficient
NeurAxis, Inc. leads the development of minimally invasive systems for the therapy of pediatric gastrointestinal issues, holding a unique FDA approval status. The P/S time series reflects the dynamics of the market valuation of revenue, with the latest mark standing at 12.20. High scalability is driven by the sale of software and equipment, while the development of a pediatric neurostimulation ecosystem ensures patient inflow through insurance coverage.
Analytical breakdowns for NeurAxis, Inc (NRXS)
- price and consensus price forecast:
- stock exchange capitalization data:
- company book value details:
- business debt structure and liquidity details:
- earnings and valuation multiples information:
NRXS - Net Income|Net Profit Forecast NeurAxis, Inc.|NRXS - Price to Earnings Ratio|Market Cap to Projected Earnings NeurAxis Inc.|NRXS - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation NeurAxis, Inc|NRXS - Operating profit EBITDA|Net earnings per one share for the last twelve months NeurAxis|NRXS - Net earnings per share for the last 12 months|Quarterly EPS earnings growth neuraxis.com|NRXS - Earnings per share growth in current year|Expected earnings per share trend next year NeurAxis, Inc.
- issuer revenue and sales details:
Summary company analytics:NRXS, neuraxis.com
The price-to-sales ratio determines the degree of deviation of an asset's current value from its actual sales volume. By analyzing the P/S trajectory, an investor assesses the premium for future growth, where inflated values signal overbought conditions and depressed values indicate stagnation. This metric measures the efficiency of business monetization through the lens of market expectations. For NeurAxis, Inc. (NRXS), this indicator reflects the value of its innovative potential within the non-invasive pediatric neuromodulation segment.
Competitors of NeurAxis, Inc.
Price-to-Revenue Coefficient biogen.com|Price-to-Revenue Ratio Neurocrine Biosciences, Inc. NBIX|Price-to-Revenue Coefficient Regencell Bioscience Ltd (RGC)|AXSM: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Corp)|XENE: P/S Multiple|VKTX - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Supernus|Market Cap to Revenue Ratio CPRX (Catalyst Pharma)|P/S Multiple DNLI|Market Cap to Revenue Harmony Corp HRMY|Biohaven Ltd. - Market Cap to Revenue|Price-to-Revenue Coefficient amylyx.com (AMLX)|TRVI - Price-to-Revenue Ratio|PRAX (Praxis Precision Medicines Inc) - Market Cap to Revenue Ratio|Anavex Corp (AVXL) - Price-to-Revenue Ratio|CeriBell EEG - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue PRTA|Market Cap to Revenue Ratio ALEC (Alector Therapeutics)|Price-to-Revenue Ratio Annexon (ANNX)|Price-to-Revenue Coefficient omeros.com|Price-to-Revenue Ratio Neurogene Corp NGNE|ACIU: Market Cap to Revenue Ratio|Voyager Therapeutics - P/S Multiple|Price to Sales neumoratx.com|SCLX (Scilex) - Market Cap to Revenue|Tevogen Bio Holdings Inc. (TVGN) - P/S Multiple|Price-to-Revenue Ratio Alpha Cognition Inc|CGTX: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Inhibikase Therapeutics (IKT)|SAVA - Price to Sales|Price-to-Revenue Ratio Assertio ASRT|COYA: Market Cap to Revenue Ratio|VistaGen Therapeutics Inc - P/S Multiple|Price to Sales Ovid Therapeutics Inc.|ABOS (Acumen Pharmaceuticals) - Market Cap to Revenue|cervomed.com (CRVO) - P/S Multiple|Price-to-Revenue Ratio Alterity Therapeutics Ltd.|CLNN: Market Capitalization-to-Revenue Ratio|P/S Multiple PEPG|P/S Multiple Jupiter Neurosciences, Inc. (JUNS)|Relmada Therapeutics - Market Cap to Revenue|ANVS: Market Cap to Revenue Ratio|Grace Tx - P/S Multiple|Price-to-Revenue Coefficient Firefly Neuroscience, Inc. AIFF|anewmeds.com (KLTO) - Price-to-Revenue Ratio|NRSN - Price-to-Revenue Coefficient|Market Cap to Revenue RVPH|MTVA: Market Capitalization-to-Revenue Ratio|P/S Multiple HSDT|Price-to-Revenue Coefficient passagebio.com|Price-to-Revenue Ratio Neuphoria Therapeutics NEUP|NERV: Market Cap to Revenue Ratio|Athira Pharma, Inc. - P/S Multiple|addextherapeutics.com (ADXN) - Market Cap to Revenue|ALZN (alzamend.com) - Market Cap to Revenue|CYCN - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Protagenic Therapeutics Inc.|Market Cap to Revenue Ratio KTTA (Pasithea)|Price-to-Revenue Ratio Cortigent, Inc. (CRGT)|ATXI (avenuetx.com) - Market Capitalization-to-Revenue Ratio|BrainStorm Cell Therapeutics - Market Cap to Revenue|CARA: Market Cap to Revenue Ratio|CHRO - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Eliem Therapeutics ELYM|intracellulartherapies.com (ITCI) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio LBPH|MRNS (Marinus Pharmaceuticals, Inc.) - P/S Multiple|Price to Sales NKGen Biotech Inc NKGN|Market Cap to Revenue NRBO (NeuroBo)|P/S Multiple Sage Therapeutics Inc (SAGE)|Price-to-Revenue Ratio Synaptogenix, Inc. SNPX|Market Capitalization-to-Revenue Ratio TRVN|VIGL - Price-to-Revenue Ratio|Price to Sales anewmeds.com|Cerevel (CERE) - Price-to-Revenue Ratio
